BIOMAT Database Logo BIOMAT Database Logo

Docetaxel-resistant prostate cancer cells remain sensitive to S-trityl-L-cysteine-mediated Eg5 inhibition. 2010

Carolyn Wiltshire, and Babloo L Singh, and Jacqueline Stockley, and Janis Fleming, and Brendan Doyle, and Robert Barnetson, and Craig N Robson, and Frank Kozielski, and Hing Y Leung
Division of Cancer Sciences and Molecular Pathology, University of Glasgow, Glasgow, United Kingdom.

Castrate-resistant prostate cancer remains a major clinical challenge. Due to the toxicity profile of taxane-based chemotherapy and treatment failure in some patients, novel agents with improved efficacy to side effect profiles are urgently needed. Eg5, a member of the kinesin-5 family, controls the formation of the bipolar spindle during cell division, and suppressed Eg5 function leads to mitotic arrest. S-Trityl-L-cysteine (STLC) is a novel Eg5-specific small-molecule inhibitor. Here, we report the first study to evaluate its use in prostate cancer. In a panel of prostate cancer cells, LNCaP and PC3 cells were the most and least sensitive to STLC treatment, with a 7.2-fold difference in their respective GI(50) values: 250 nmol/L and 1.8 micromol/L. In LNCaP cells, treatment with either STLC or docetaxel resulted in transient G(2)-M arrest and subsequent caspase-mediated cell death. However, STLC- and docetaxel-treated PC3M cells have distinct fates: STLC induced a transient G(2)-M arrest, followed by polyploidy; in contrast, docetaxel-treated PC3M cells progressed to apoptosis after a transient G(2)-M arrest. Docetaxel-resistant LNCaP-derived (LDocR) cells respond to STLC in a similar manner to the parental cells. Although the docetaxel-resistant PC3M-derived (PDocR) cell line and its parental PC3M cells have similar GI(50) to STLC treatment, PDocR cells showed significantly more G(2)-M arrest and less apoptosis. Hence, although docetaxel-resistant prostate cancer cells remain responsive to Eg5 inhibition with STLC, there are key differences at the cell cycle level, which may have implication in future development.

UI MeSH Term Description Entries
D008297 Male Males
D011419 Propidium Quaternary ammonium analog of ethidium; an intercalating dye with a specific affinity to certain forms of DNA and, used as diiodide, to separate them in density gradients; also forms fluorescent complexes with cholinesterase which it inhibits. Propidium Diiodide,Propidium Iodide,Diiodide, Propidium,Iodide, Propidium
D011471 Prostatic Neoplasms Tumors or cancer of the PROSTATE. Cancer of Prostate,Prostate Cancer,Cancer of the Prostate,Neoplasms, Prostate,Neoplasms, Prostatic,Prostate Neoplasms,Prostatic Cancer,Cancer, Prostate,Cancer, Prostatic,Cancers, Prostate,Cancers, Prostatic,Neoplasm, Prostate,Neoplasm, Prostatic,Prostate Cancers,Prostate Neoplasm,Prostatic Cancers,Prostatic Neoplasm
D003545 Cysteine A thiol-containing non-essential amino acid that is oxidized to form CYSTINE. Cysteine Hydrochloride,Half-Cystine,L-Cysteine,Zinc Cysteinate,Half Cystine,L Cysteine
D004354 Drug Screening Assays, Antitumor Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals. Anticancer Drug Sensitivity Tests,Antitumor Drug Screens,Cancer Drug Tests,Drug Screening Tests, Tumor-Specific,Dye Exclusion Assays, Antitumor,Anti-Cancer Drug Screens,Antitumor Drug Screening Assays,Tumor-Specific Drug Screening Tests,Anti Cancer Drug Screens,Anti-Cancer Drug Screen,Antitumor Drug Screen,Cancer Drug Test,Drug Screen, Anti-Cancer,Drug Screen, Antitumor,Drug Screening Tests, Tumor Specific,Drug Screens, Anti-Cancer,Drug Screens, Antitumor,Drug Test, Cancer,Drug Tests, Cancer,Screen, Anti-Cancer Drug,Screen, Antitumor Drug,Screens, Anti-Cancer Drug,Screens, Antitumor Drug,Test, Cancer Drug,Tests, Cancer Drug,Tumor Specific Drug Screening Tests
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077143 Docetaxel A semisynthetic analog of PACLITAXEL used in the treatment of locally advanced or metastatic BREAST NEOPLASMS and NON-SMALL CELL LUNG CANCER. Docetaxel Anhydrous,Docetaxel Hydrate,Docetaxel Trihydrate,Docetaxol,N-Debenzoyl-N-tert-butoxycarbonyl-10-deacetyltaxol,NSC 628503,RP 56976,RP-56976,Taxoltere Metro,Taxotere,N Debenzoyl N tert butoxycarbonyl 10 deacetyltaxol,RP56976
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D015854 Up-Regulation A positive regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins. Receptor Up-Regulation,Upregulation,Up-Regulation (Physiology),Up Regulation
D016547 Kinesins A family of microtubule-associated mechanical adenosine triphosphatases, that uses the energy of ATP hydrolysis to move organelles along microtubules including mitosis, meiosis, and axonal transport. Kinesin,Kinesin Heavy-Chain Protein,Kinesin Light-Chain Protein,Kinesin Light-Chain Proteins,Kinesin Superfamily,Heavy-Chain Protein, Kinesin,Light-Chain Protein, Kinesin,Light-Chain Proteins, Kinesin,Protein, Kinesin Heavy-Chain,Protein, Kinesin Light-Chain,Proteins, Kinesin Light-Chain,Superfamily, Kinesin

Related Publications

Carolyn Wiltshire, and Babloo L Singh, and Jacqueline Stockley, and Janis Fleming, and Brendan Doyle, and Robert Barnetson, and Craig N Robson, and Frank Kozielski, and Hing Y Leung
Doing the methylene shuffle--further insights into the inhibition of mitotic kinesin Eg5 with S-trityl L-cysteine.
August 2012, European journal of medicinal chemistry,
Carolyn Wiltshire, and Babloo L Singh, and Jacqueline Stockley, and Janis Fleming, and Brendan Doyle, and Robert Barnetson, and Craig N Robson, and Frank Kozielski, and Hing Y Leung
Structural modification of S-trityl-L-cysteine. Preparation of some S-(substituted trityl)-L-cysteines and dipeptides of S-trityl-L-cysteine.
January 1972, Journal of medicinal chemistry,
Carolyn Wiltshire, and Babloo L Singh, and Jacqueline Stockley, and Janis Fleming, and Brendan Doyle, and Robert Barnetson, and Craig N Robson, and Frank Kozielski, and Hing Y Leung
S-trityl-L-cysteine, a novel Eg5 inhibitor, is a potent chemotherapeutic strategy in neuroblastoma.
July 2018, Oncology letters,
Carolyn Wiltshire, and Babloo L Singh, and Jacqueline Stockley, and Janis Fleming, and Brendan Doyle, and Robert Barnetson, and Craig N Robson, and Frank Kozielski, and Hing Y Leung
Structure-activity relationship of S-trityl-L-cysteine analogues as inhibitors of the human mitotic kinesin Eg5.
March 2008, Journal of medicinal chemistry,
Carolyn Wiltshire, and Babloo L Singh, and Jacqueline Stockley, and Janis Fleming, and Brendan Doyle, and Robert Barnetson, and Craig N Robson, and Frank Kozielski, and Hing Y Leung
A potent chemotherapeutic strategy in prostate cancer: S-(methoxytrityl)-L-cysteine, a novel Eg5 inhibitor.
March 2011, Asian journal of andrology,
Carolyn Wiltshire, and Babloo L Singh, and Jacqueline Stockley, and Janis Fleming, and Brendan Doyle, and Robert Barnetson, and Craig N Robson, and Frank Kozielski, and Hing Y Leung
Photocontrol of the mitotic kinesin Eg5 using a novel S-trityl-L-cysteine analogue as a photochromic inhibitor.
April 2014, Journal of biochemistry,
Carolyn Wiltshire, and Babloo L Singh, and Jacqueline Stockley, and Janis Fleming, and Brendan Doyle, and Robert Barnetson, and Craig N Robson, and Frank Kozielski, and Hing Y Leung
Structure-activity relationship and multidrug resistance study of new S-trityl-L-cysteine derivatives as inhibitors of Eg5.
March 2011, Journal of medicinal chemistry,
Carolyn Wiltshire, and Babloo L Singh, and Jacqueline Stockley, and Janis Fleming, and Brendan Doyle, and Robert Barnetson, and Craig N Robson, and Frank Kozielski, and Hing Y Leung
Inhibition of hepatitis C virus NS5B polymerase by S-trityl-L-cysteine derivatives.
March 2012, European journal of medicinal chemistry,
Carolyn Wiltshire, and Babloo L Singh, and Jacqueline Stockley, and Janis Fleming, and Brendan Doyle, and Robert Barnetson, and Craig N Robson, and Frank Kozielski, and Hing Y Leung
Proteome analysis of apoptosis signaling by S-trityl-L-cysteine, a potent reversible inhibitor of human mitotic kinesin Eg5.
January 2008, Proteomics,
Carolyn Wiltshire, and Babloo L Singh, and Jacqueline Stockley, and Janis Fleming, and Brendan Doyle, and Robert Barnetson, and Craig N Robson, and Frank Kozielski, and Hing Y Leung
Mutations in the human kinesin Eg5 that confer resistance to monastrol and S-trityl-L-cysteine in tumor derived cell lines.
March 2010, Biochemical pharmacology,
Copied contents to your clipboard!